New data refine the choice between ropinirole and apomorphine

CURRENT BRIEF VERSION: A new 2025 study adds fresh data to a longstanding clinical question in toxicology and emergency practice: when a dog needs emesis induced, how does ophthalmic ropinirole compare with apomorphine? In a crossover study of 24 healthy dogs published in Frontiers in Veterinary Science on March 17, 2025, investigators found no significant difference in overall emesis success between IV apomorphine and ophthalmic ropinirole after up to two doses, with success rates of 95.8% and 100%, respectively. But apomorphine acted faster and produced a shorter vomiting period, while ropinirole was associated with more vomiting episodes and a much higher need for early antiemetic rescue. That nuance matters because ropinirole, marketed as Clevor, remains the only FDA-approved emetic for dogs in the U.S., while apomorphine is still used extra-label for this purpose. A separate 2025 emergency-room study discussed by VetGirl, involving 132 client-owned dogs at two specialty hospitals, points in a similar direction: dogs were randomized after suspected toxin or foreign-body ingestion, re-dosed if they had not vomited within 20 minutes, and monitored for 40 minutes, underscoring how these drug differences play out in real emergency presentations rather than only in healthy research dogs. (frontiersin.org)

Why it matters: For veterinary professionals, the takeaway isn't simply that the two drugs "work." It's that they differ in workflow, speed, and adverse-effect profile. Clevor offers a labeled, ready-to-use, injection-free option administered by a veterinary professional, which can simplify handling and avoid compounding. Apomorphine, meanwhile, may still be attractive in urgent toxin or foreign-body cases because it produced emesis more quickly and with a shorter duration in the 2025 trial. Other published and educational sources also note that ropinirole can be practical, but may bring more prolonged vomiting or ocular effects, reinforcing the need to match the agent to the patient, contraindications, and clinic setup. And because prolonged or repeated emesis may increase the need for rescue therapy, antiemetic availability is part of the workflow too; for example, Dechra says its newly approved maropitant injectable, Emeprev, is an FDA-approved bioequivalent antiemetic for dogs and cats that does not require refrigeration and is designed to reduce injection pain in dogs. (vetoquinolusa.com)

What to watch: Expect more discussion around protocol selection, rescue antiemetic use, and whether real-world emergency data shift practice toward one agent over the other in specific case types. The 132-dog specialty-hospital trial highlighted by VetGirl may help answer that, especially in cases involving toxic foods, medications, plants, rodenticides, and foreign material. (pubmed.ncbi.nlm.nih.gov)